Andreas Zehetner
Andreas Zehetner has been intensively engaged in various trading strategies since 2015 and is himself a passionate trend-following trader. In webinars and short video coaching sessions, he regularly presents different analysis methods. Focusing on the US market, Andreas identifies interesting breakout opportunities in leading growth stocks as part of the NEO-DARVAS strategy and based on the frameworks of legends like William O’Neil or Mark Minervini.
Latest from Andreas Zehetner
Vertiv with 30% Price Potential – Goldman expects twice +38% in power demand from US data centers
BMO Capital sees a 30% price potential for Vertiv and considers it one of the best beneficiaries of...
United Therapeutics: The Patent Victory Eases the Path to $1,000
United Therapeutics (UTHR) is back on my radar after the surprising patent victory against Liquidia...
Cohu triples by 2026 – annual 850 million USD AI pipeline opens further growth potential
Cohu directly benefits from the expansion of AI data centers and HBM memory with test and inspection...
AI Power Hunger Drives Vistra Energy – $4.2 Billion for Increased Nuclear Capacity
The US government plans to lend Vistra approximately $4.2 billion to increase the output of existing...
Twilio remains my favorite – why the agentic AI potential is just becoming visible
Meta (i) demonstrates with Muse why the Twilio story (TWLO, i) is just beginning. The personal AI agent...
PBF Energy Reaches All-Time High – Diesel Shortage Causes Margins to Explode
PBF Energy benefits from extremely high refining margins as diesel and other fuels remain scarce worldwide....
Cheaper despite competing offers – onsemi builds the next AI growth story with Synaptics
onsemi sweetens the Synaptics deal: Instead of the previous stock deal, the company will pay 123 USD...
MongoDB: Why I See the CEO Shock as an Entry Opportunity
MongoDB (MDB) is particularly intriguing for me again after the surprising switch of CEO CJ Desai to...
Vicor: Forecast Raised Twice in Nine Days – VPD Licensing Business Takes Off
Vicor raises its forecast for Q3 for the second time in nine days. Instead of more than 20%, sequential...
Orion Reaches All-Time High – Blockbuster Nubeqa Drives Profit Surge
Orion is a Finnish pharmaceutical company that develops its own medications and also earns income from...
Precigen: PAPZIMEOS takes off – $2 billion opportunity gains momentum
Precigen sees global peak sales potential for PAPZIMEOS of more than $2 billion and holds market exclusivity...
United Therapeutics wins important patent dispute – Yutrepia under pressure with PH-ILD
United Therapeutics wins an important patent dispute against Liquidia. Yutrepia could lose its PH-ILD...
Synopsys Raises Long-Term Goals – New Royalties, Amazon Deal, and GPT-Synopsys Drive Growth
Synopsys expects an annual revenue growth of around 15% by 2030. EPS and free cash flow are projected...
Howmet Aerospace: Buying opportunity despite SpaceX and GE concerns? Citi sees over 40% potential
Citi places Howmet Aerospace on the "Upside 90-Day Catalyst Watch” and reaffirms its buy rating with...
Marvell: The Most Exciting Indirect Beneficiary of Anthropic's $518 Billion AI Offensive
Marvell Technology (MRVL) is seen as a particularly exciting indirect beneficiary of Anthropic's infrastructure...
IDT Corporation: From Telecom Company to Fintech and AI Platform – Stock Reaches All-Time High
IDT is transforming from a traditional telecom company into a platform for fintech, point-of-sale systems,...
AMD Accelerates AI Offensive: Helios, Anthropic, and $8.2 Billion Acquisition
AMD wins billion-dollar AI contracts with OpenAI, Meta, and Anthropic, expanding Helios as an alternative...
Tesla secures $30 billion – AI, proprietary chips, and robotaxis drive investment offensive
Tesla secures credit lines of $30 billion, providing additional financial flexibility for an exceptionally...
IQVIA: Record Drug Approvals Highlight Growing Importance in the Age of AI
For me, the strategic significance of IQVIA Holdings (IQV, i) is clearly increasing in the age of AI....
AbbVie: Back on Growth Path After Humira – New Billion-Dollar Potentials and P/E 16.4
AbbVie is a leading biopharmaceutical company and is increasingly offsetting the decline of Humira...